Skip to content
Back Home

North Carolina Pregnancy & Opioid Exposure Project

North Carolina Pregnancy & Opioid Exposure Project

  • Background
  • About
  • Key Messages
    • Infant Care Providers Working with Families of an Opioid-Exposed Newborn
    • Women of Childbearing Age and Pregnant Women Who are Taking Opioids
    • Providers Working with Women of Childbearing Age or Pregnant Women Who are Taking Opioids
  • Guidance for NC
  • Resources
  • Services
Home » Pregnancy and Opioid Exposure: Guidance for North Carolina » North Carolina Guidelines: Medication Assisted Treatment (MAT) in Pregnancy » Resources for Office-Based Treatment for Opioid Dependence with Buprenorphine
  • Scope of the Issue
  • Overview of Pregnancy and Opioid Exposure
  • Treatment Matters
    • What is Substance-Use Disorder Treatment?
    • Six Dimensions
    • Approaches to Treatment
    • NC Perinatal and Maternal Substance abuse and the CASAWORKS for Families Residential Initiatives
  • North Carolina Guidelines: Medication Assisted Treatment (MAT) in Pregnancy
    • Medication-Assisted Treatment (MAT) in Pregnancy – Overview
    • Methadone: Opioid Treatment Program (OTP)
    • Buprenorphine: Office-Based Medication-Assisted Treatment or OTP
    • Medication Selection
    • Medication Management
    • Breastfeeding
    • Postpartum Plan for Opioid-Agonist Medication
    • Contraception and Fertility
    • Common Clinical Challenges
    • Clinical Risk Management Strategies
    • Provider Information and Supports
    • Risk Management References
    • Resources for Office-Based Treatment for Opioid Dependence with Buprenorphine
    • Appendices
  • Medicaid Coverage and State-Funded Services
  • Neonatal Abstinence Syndrome Overview
    • Opioid Addiction
    • Opioids and Pregnancy
    • Neonatal Abstinence Syndrome (NAS)
    • Appendix A: Neonatal Abstinence Syndrome (NAS) Scoring Explanation
  • Reviewer Acknowledgement

Resources for Office-Based Treatment for Opioid Dependence with Buprenorphine

Substance Abuse and Mental Health Services Administration. TIP 40: clinical guidelines for the use of buprenorphine in the treatment of opioid addiction (Publication No. SMA07-3939). Rockville, MD. 2004.

Vermont Department of Health, Division of Alcohol and Drug Abuse Programs; Department of Vermont Health Access. Vermont buprenorphine practice guidelines.

How to Talk with Women Who are Pregnant about Opioid Use

NCPOEP_toolkit

 

NC Perinatal and Maternal Substance abuse and the CASAWORKS for Families Residential Initiatives

NCPOEP_toolkit

 

Pregnancy and Opioid Exposure: Guidance for North Carolina

NCPOEP_toolkit

 

© 2018 North Carolina Pregnancy & Opioid Exposure Project | Contact Us

School of Social Work | University of North Carolina at Chapel Hill

UNC SSW logo

A project of the NC Division of Mental Health, Developmental Disabilities and Substance Abuse Services

NC Division of Mental Health, Developmental Disabilities and Substance Abuse Services

Funded by the federal Substance Abuse Prevention and Treatment Block Grant Fund (CFDA #93.959) as a project of the NC Division of Mental Health, Developmental Disabilities & Substance Abuse Services

· © 2022 NCPOEP · Powered by · Designed with the Customizr theme ·